GRAIL (GRAL) Projected to Post Earnings on Wednesday

GRAIL (NASDAQ:GRAL) is anticipated to issue its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect GRAIL to post earnings of ($2.45) per share and revenue of $44.21 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

GRAIL (NASDAQ:GRAL) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($2.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.66) by $0.10. The firm had revenue of $44.69 million during the quarter, compared to analysts’ expectations of $42.39 million. On average, analysts expect GRAIL to post ($10.07) EPS for the current fiscal year and ($10.80) EPS for the next fiscal year.

GRAIL Stock Up 5.1%

Shares of NASDAQ:GRAL traded up $7.64 during trading on Wednesday, hitting $158.25. The stock had a trading volume of 230,451 shares, compared to its average volume of 969,547. GRAIL has a 12-month low of $41.50 and a 12-month high of $166.48. The stock has a market capitalization of $7.07 billion, a price-to-earnings ratio of -16.21 and a beta of 2.83. The stock has a 50-day simple moving average of $107.27 and a two-hundred day simple moving average of $77.77.

Analyst Ratings Changes

A number of brokerages recently commented on GRAL. Mizuho upped their target price on GRAIL from $65.00 to $100.00 and gave the company a “neutral” rating in a research report on Friday, September 25th. Morgan Stanley raised their price target on shares of GRAIL from $60.00 to $120.00 and gave the stock an “equal weight” rating in a research report on Monday, October 12th. Weiss Ratings restated a “sell (d-)” rating on shares of GRAIL in a research note on Thursday, October 15th. TD Cowen lifted their price objective on shares of GRAIL from $88.00 to $180.00 and gave the company a “buy” rating in a research note on Tuesday, October 13th. Finally, UBS Group upped their price objective on shares of GRAIL from $105.00 to $175.00 and gave the company a “buy” rating in a report on Friday, October 2nd. Five research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, GRAIL has a consensus rating of “Hold” and an average price target of $119.80.

Insider Buying and Selling

In other GRAIL news, CFO Aaron Freidin sold 23,619 shares of the firm’s stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $146.39, for a total value of $3,457,585.41. Following the sale, the chief financial officer directly owned 225,364 shares of the company’s stock, valued at approximately $32,991,035.96. This trade represents a 9.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Joshua J. Ofman sold 61,452 shares of the business’s stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $97.74, for a total value of $6,006,318.48. Following the completion of the sale, the chief executive officer owned 362,271 shares of the company’s stock, valued at $35,408,367.54. This trade represents a 14.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 129,944 shares of company stock valued at $14,832,805. 1.83% of the stock is owned by company insiders.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a healthcare company focused on developing blood-based screening technologies for the early detection of cancer. Its principal product is Galleri, a multi-cancer early detection test designed to identify DNA patterns associated with multiple types of cancer from a single blood sample.

Galleri is intended for use alongside recommended cancer screenings and is available by prescription through qualified healthcare providers in the United States. The test is offered as a laboratory-developed test and has not been approved or cleared by the U.S.